On 21 May 2026, IFPMA published a statement on the follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases, on the margins of the World Health Assembly. IFPMA welcomes WHO’s continued efforts to tackle one of the greatest health challenges of our lifetimes....
Read moreOn 18 May 2026, IFPMA delivered a statement on the Open-Ended Intergovernmental Working Group on the WHO Pandemic Agreement at the 79th World Health Assembly in Geneva. The innovative pharmaceutical industry remains a critical partner in pandemic preparedness and response, with a strong track record of action during pandemics and Public Health Emergencies of International...
Read moreOn 14 May 2026 in New York City, IFPMA delivered a statement at the Multi-Stakeholder Hearing ahead of the UN High-Level Meeting on HIV/AIDS. The 2026 High-Level Meeting comes at a sensitive but important moment for the global HIV response. Meaningful progress has been made, but it remains fragile, uneven, and vulnerable to reversal if...
Read moreOn 30 April 2026, IFPMA delivered a statement at the Sixth resumed meeting of the open-ended Intergovernmental Working Group (IGWG 6) on the WHO Pandemic Agreement.
Read moreAs WTO Members gather in Yaoundé for the 14th Ministerial Conference (MC14), the meeting comes at a pivotal moment for global trade and health.
Read moreOn 23 March 2026, IFPMA delivered a statement at the Sixth meeting of the open-ended Intergovernmental Working Group (IGWG 6) on the WHO Pandemic Agreement.
Read moreThe global innovative pharmaceutical industry recognizes the increasing interest from health systems, procurers, and policymakers in understanding the environmental footprint of medicines and vaccines. As conversations evolve around product-level life cycle assessment (LCA), it is vital that any emerging frameworks support clarity, methodological consistency, and insights that enable companies to improve their own environmental performance....
Read moreOn 9 February 2026 in Geneva, IFPMA delivered a statement at the fifth meeting of the open-ended Intergovernmental Working Group (IGWG 5) on the WHO Pandemic Agreement.
Read moreOn 6 February 2026, IFPMA delivered a statement on Agenda item 29.1 on reform of the global health architecture at the 158th session of the WHO Executive Board in Geneva. The innovative pharmaceutical industry views this process as a critical opportunity to build a stronger, truly fit-for-purpose global health architecture. As a trusted and official...
Read moreWe appreciate the opportunity to contribute to the discussions at EB158. WHO’s work on strengthening emergency preparedness reflects a shared commitment to ensuring the world is better equipped for future health threats. We welcome this direction and the emphasis on clarity, coordination, and readiness. As EB158 documents highlight, WHO will now take on an expanded set of responsibilities...
Read moreOn 4 February 2026, IFPMA delivered a statement on Agenda item 14 on the draft updated global action plan on antimicrobial resistance (AMR) at the 158th session of the WHO Executive Board. We welcome the timely update of the Global Action Plan on AMR (GAP), which provides a unique opportunity to take stock of progress...
Read moreOn 4 February 2026, IFPMA delivered a statement on Agenda item 15 on harmonization of regulatory approaches, governance, and standards for data, digital health, and artificial intelligence in the health sector at the 158th session of the WHO Executive Board in Geneva. Noting the work carried out by several multilateral institutions on digital health transformation,...
Read more